Jasper Therapeutics (NASDAQ:JSPR) Given Market Outperform Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report sent to investors on Monday,Benzinga reports. They currently have a $70.00 price target on the stock.

Several other equities research analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $68.00 price objective on shares of Jasper Therapeutics in a research note on Monday, December 23rd. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $73.38.

Jasper Therapeutics Stock Down 60.5 %

Jasper Therapeutics stock opened at $6.99 on Monday. The stock has a market cap of $104.86 million, a price-to-earnings ratio of -1.47 and a beta of 2.18. Jasper Therapeutics has a 12-month low of $6.61 and a 12-month high of $31.01. The business’s 50-day simple moving average is $21.66 and its 200 day simple moving average is $20.37.

Hedge Funds Weigh In On Jasper Therapeutics

Several institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets increased its stake in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Jasper Therapeutics in the third quarter valued at approximately $59,000. MetLife Investment Management LLC increased its position in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics during the second quarter worth $300,000. Finally, Jane Street Group LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth $251,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.